Antimicrobial agents and chemotherapy, vol 61, iss 8 Nayak, SU; Griffiss, JM; Blumer, J; O'Riordan, MA; Gray, W; McKenzie, R; et al.(2017). Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a MethionyltRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(8). doi: 10.1128/AAC.02760-16. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/98p1w1q6